Dr. Reddy's Laboratories Limited (RDY) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 6 Buy, 4 Hold, 2 Sell.
Analysts estimate Earnings Per Share (EPS) of $0.69 and revenue of $3.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $66.80 vs est $0.69 (beat +9535.7%). Analyst accuracy: 1%.
RDY Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Dr. Reddy's Laboratories Limited in the past 3 months
EPS Estimates — RDY
1%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $66.80
vs Est $0.69
▲ 99.0% off
2025
Actual $0.00
vs Est $0.73
▼ 0.0% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — RDY
1%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $279.164B
vs Est $2.995B
▲ 98.9% off
2025
Actual $325.535B
vs Est $3.470B
▲ 98.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
